Mechanistically, LINC01133 acts as key downstream molecule in the TGF-β pathway and inhibits the EMT in colorectal cancer by directly binding to SRSF6 (serine and arginine rich splicing factor 6) as a target mimic. Here, LINC01133 is linked to colorectal cancer.